Nabazenil
Izgled
(IUPAC) ime | |||
---|---|---|---|
(6,6,9-trimetil-3-(3-metiloktan-2-il)-7,8,9,10-tetrahidrobenzo[c]hromen-1-yl)-4-(azepan-1-il)butanoat | |||
Klinički podaci | |||
Identifikatori | |||
CAS broj | 58019-65-1 | ||
ATC kod | nije dodeljen | ||
PubChem[1][2] | 163326 | ||
UNII | N1RX70K36C | ||
Hemijski podaci | |||
Formula | C35H55NO3 | ||
Mol. masa | 537,814 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status |
Nabazenil (SP-175) je sintetički agonist kanabinoidnog receptora, koji poseduje antikonvulsivna svojstva.[3][4]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Concise dictionary of pharmacological agents: properties and synonyms. p188. ISBN 0-7514-0499-3
- ↑ N. Aboul-Enein, M.; A. El-Azzouny, A.; A. Saleh, O.; A. Maklad, Y. (June 2012). „On Chemical Structures with Potent Antiepileptic/Anticonvulsant Profile”. Mini Reviews in Medicinal Chemistry (Bentham Science Publishers) 12 (7): 671-700.